Literature DB >> 17983731

Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons.

Stephan Rüegg1, Marianna Baybis, Hal Juul, Marc Dichter, Peter B Crino.   

Abstract

PURPOSE: We assayed the effects of rapamycin, an immunomodulatory agent known to inhibit the activity of the mammalian target of rapamycin (mTOR) cascade, on candidate gene expression and single unit firing properties in cultured rat hippocampal neurons as a strategy to define the effects of rapamycin on neuronal gene transcription and excitability.
METHODS: Rapamycin was added (100nM) to cultured hippocampal neurons on days 3 and 14. Neuronal somatic size and dendritic length were assayed by immunohistochemistry and digital imaging. Radiolabeled mRNA was amplified from single hippocampal pyramidal neurons and used to probe cDNA arrays containing over 100 distinct candidate genes including cytoskeletal element, growth factor, transcription factor, neurotransmitter, and ion channel genes. In addition, the effects of rapamycin (200nM) on spontaneous neuronal activity and voltage-dependent currents were assessed.
RESULTS: There were no effects of rapamycin on cell size or dendrite length. Rapamycin altered expression of distinct mRNAs in each gene family on days 3 and 14 in culture. Single unit recordings from neurons exposed to rapamycin exhibited no change from baseline. When spontaneous activity was increased by blocking GABA-mediated inhibition with bicuculline, a fraction of the neurons exhibited a decreased duration of spontaneous bursts and a decrease in synaptic inputs. Rapamycin did not appear to alter voltage-dependent Na(+) or K(+) currents underlying action potentials.
CONCLUSIONS: These data demonstrate that rapamycin does not produce neurotoxicity nor alter dendritic growth and complexity in vitro and does not significantly alter voltage-gated sodium and potassium currents. Rapamycin does affect neuronal gene transcription in vitro. Use of rapamycin in clinical trials for patients with tuberous sclerosis complex warrants vigilance for possible effects on seizure frequency and neurocognitive function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17983731      PMCID: PMC3474316          DOI: 10.1016/j.eplepsyres.2007.09.009

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  37 in total

1.  Preparation of cDNA from single cells and subcellular regions.

Authors:  J E Kacharmina; P B Crino; J Eberwine
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

Review 2.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

Review 3.  The tuberous sclerosis complex.

Authors:  Peter B Crino; Katherine L Nathanson; Elizabeth Petri Henske
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

4.  A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus.

Authors:  Shao Jun Tang; Gerald Reis; Hyejin Kang; Anne-Claude Gingras; Nahum Sonenberg; Erin M Schuman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

5.  Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers.

Authors:  R White; Y Hua; B Scheithauer; D R Lynch; E P Henske; P B Crino
Journal:  Ann Neurol       Date:  2001-01       Impact factor: 10.422

6.  Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex.

Authors:  Patrick F Bolton; Rebecca J Park; J Nicholas P Higgins; Paul D Griffiths; Andrew Pickles
Journal:  Brain       Date:  2002-06       Impact factor: 13.501

7.  Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma.

Authors:  Nisreen El-Hashemite; Hongbing Zhang; Elizabeth P Henske; David J Kwiatkowski
Journal:  Lancet       Date:  2003-04-19       Impact factor: 79.321

Review 8.  Benefit-risk assessment of sirolimus in renal transplantation.

Authors:  Dirk R J Kuypers
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

9.  mTOR cascade activation distinguishes tubers from focal cortical dysplasia.

Authors:  Marianna Baybis; Jia Yu; Allana Lee; Jeff A Golden; Howard Weiner; Guy McKhann; Eleonora Aronica; Peter B Crino
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

10.  Hydrogen peroxide modulation of synaptic plasticity.

Authors:  Ariel Kamsler; Menahem Segal
Journal:  J Neurosci       Date:  2003-01-01       Impact factor: 6.167

View more
  33 in total

1.  Disrupting function of FK506-binding protein 1b/12.6 induces the Ca²+-dysregulation aging phenotype in hippocampal neurons.

Authors:  John C Gant; Kuey-Chu Chen; Christopher M Norris; Inga Kadish; Olivier Thibault; Eric M Blalock; Nada M Porter; Philip W Landfield
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

2.  A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

Authors:  Emmanuel Raffo; Antonietta Coppola; Tomonori Ono; Stephen W Briggs; Aristea S Galanopoulou
Journal:  Neurobiol Dis       Date:  2011-04-12       Impact factor: 5.996

Review 3.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

4.  Rapamycin for treatment of epilepsy: antiseizure, antiepileptogenic, both, or neither?

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2011-03       Impact factor: 7.500

Review 5.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 6.  Therapeutic approaches to epileptogenesis--hope on the horizon.

Authors:  Asla Pitkänen
Journal:  Epilepsia       Date:  2010-07       Impact factor: 5.864

7.  Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.

Authors:  Cristina Malagelada; Zong Hao Jin; Vernice Jackson-Lewis; Serge Przedborski; Lloyd A Greene
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

8.  Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder.

Authors:  Whitney E Parker; Ksenia A Orlova; William H Parker; Jacqueline F Birnbaum; Vera P Krymskaya; Dmitry A Goncharov; Marianna Baybis; Jelte Helfferich; Kei Okochi; Kevin A Strauss; Peter B Crino
Journal:  Sci Transl Med       Date:  2013-04-24       Impact factor: 17.956

9.  How does the ketogenic diet work? Four potential mechanisms.

Authors:  Nika N Danial; Adam L Hartman; Carl E Stafstrom; Liu Lin Thio
Journal:  J Child Neurol       Date:  2013-05-13       Impact factor: 1.987

10.  Impact of rapamycin on status epilepticus induced hippocampal pathology and weight gain.

Authors:  Michael S Hester; Bethany E Hosford; Victor R Santos; Shatrunjai P Singh; Isaiah J Rolle; Candi L LaSarge; John P Liska; Norberto Garcia-Cairasco; Steve C Danzer
Journal:  Exp Neurol       Date:  2016-03-17       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.